Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients

RATIONALE & OBJECTIVE: In the PRO(2)TECT trials, vadadustat was found to be noninferior to darbepoetin alfa in hematologic efficacy but not for major adverse cardiovascular events (MACE; all-cause death or nonfatal myocardial infarction or stroke) in patients with non–dialysis-dependent chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Parfrey, Patrick S., Burke, Steven K., Chertow, Glenn M., Eckardt, Kai-Uwe, Jardine, Alan G., Lewis, Eldrin F., Luo, Wenli, Matsushita, Kunihiro, McCullough, Peter A., Minga, Todd, Winkelmayer, Wolfgang C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329165/
https://www.ncbi.nlm.nih.gov/pubmed/37427292
http://dx.doi.org/10.1016/j.xkme.2023.100667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329165/
https://www.ncbi.nlm.nih.gov/pubmed/37427292
http://dx.doi.org/10.1016/j.xkme.2023.100667

Ejemplares similares